Glenmark Pharma to launch breast cancer treatment injection in US this September

, US subsidiary is set to launch Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, in September 2025, marking its entry into complex generics in the US institutional segment. The drug is the therapeutic equivalent of Halaven, a widely used breast cancer treatment that recorded sales of about $66.3 million in the 12 months ended July 2025, according to IQVIA. This launch underscores Glenmark’s focus on expanding its oncology portfolio and delivering affordable, high-quality treatment options. The company recently also announced the US launch of Micafungin for Injection USP, 50 mg and 100 mg vials, used for severe fungal infections, with distribution beginning in September. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.